clinical trial · NCT06905873
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
VitiligoFB102Placebo
brief summary
A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.
started
Mar 25, 2025
primary completion
Dec 31, 2026
completion
Dec 31, 2026
last updated
Nov 20, 2025
detailed description
Approximately 64 participants who meet all the screening eligibility criteria will be randomized to receive FB102 or placebo.
official title
A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-Segmental Vitiligo
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol